Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) – Nadunolimab receives FDA Fast Track designation
Published by Arron Aatkar, PhD

Cantargia has been granted Fast Track designation by the US FDA for its lead antibody candidate, nadunolimab, for metastatic pancreatic ductal adenocarcinoma. This regulatory designation is intended to expedite the development and review process for drug candidates addressing serious conditions with unmet medical needs. The decision was supported by data from the Phase I/IIa CANFOUR trial, where nadunolimab showed encouraging efficacy and safety signals. Fast Track status allows for more frequent interactions with the FDA and potential for rolling review, which may expedite time to market. This is a significant regulatory milestone that has the potential to de-risk nadunolimab’s path forward in a highly challenging cancer indication.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.